Pfizer drops Xeljanz patent suits

Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration (FDA) of plans to launch their own version of Xeljanz XR (tofacitinib).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Pfizer’s pregabalin litigation: the latest twist

15 February 2023 The long-running legal saga between the pharma giant and the NHS as well as generic drug makers has developed further, as Darren Smyth of EIP explains.

Generics

Pfizer sues MSN Labs over Xeljanz generic

9 June 2022 Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz, used to treat patients with arthritis.

Big Pharma

Pfizer commits to offer drugs not-for-profit to 45 low-income countries

31 May 2022 Pfizer has announced that it will provide all of its current and future patent-protected medicines and vaccines—that are available in the US or EU—on a not-for-profit basis to 45 lower-income countries.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Pfizer drops Xeljanz patent suits

More on this story

Editor's picks

Editor's picks

More features